Clinical effects of different protamine doses after cardiopulmonary bypass

Asian Cardiovascular and Thoracic Annals

Volumn 10, Issue 2, 2002, Pages 119-123

  Svenarud, Peter ^a   Øvrum, Eivind ^a  

^a Oslo Heart Center   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PROTAMINE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BOLUS INJECTION; CARDIOPULMONARY BYPASS; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART DISEASE; HEMOGLOBINOPATHY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; REOPERATION; RETROSPECTIVE STUDY; STERNOTOMY; SURGICAL DRAINAGE;

AGED; ANTICOAGULANTS; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; FEMALE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROTAMINES; RETROSPECTIVE STUDIES;

EID: 0036283993     PISSN: 02184923     EISSN: None     Source Type: Journal    
DOI: 10.1177/021849230201000206     Document Type: Article

References (19)

1. Monitoring heparin anticoagulation and its neutralization
2. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols
3. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage
4. The impact of heparin concentration and activated clotting time monitoring on blood conservation: A prospective, randomized evaluation in patients undergoing cardiac operation
5. Consistent non-pharmacologic blood conservation in primary and reoperative coronary artery bypass grafting
6. Autotransfusion in coronary artery bypass grafting: Disparity in laboratory tests and clinical performance
7. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients
8. Protamine - The need to determine the dose. Comparison of a simple protamine titration method with an empirical dose regimen for reversal of heparinisation following cardiopulmonary bypass
9. Comparison of two protocols for heparin neutralization by protamine after cardiopulmonary bypass
10. Hemodynamic effects of intraaortic versus intravenous protamine administration after cardiopulmonary bypass in man
11. Studies on the chemistry of blood coagulation
12. Platelet aggregation following heparin and protamine administration
13. Is protamine a clinically important anticoagulant? A negative answer
14. Neutralization of heparin in vivo with protamine. A simple method for estimating the required dose
15. Activated partial thromboplastin time-protamine dose relation in the presence and absence of heparin
16. The neutralization of heparin by protamine in extracorporeal circulation
17. De-heparinisation of blood after cardiopulmonary bypass
18. The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation
19. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations